NEUROCRINE BIOSCIENCES, INC.
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 600
- Registration Number
- NCT06966401
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 284
- Registration Number
- NCT06963034
- Locations
- 🇺🇸
Neurocrine Clinical Site, Marlton, New Jersey, United States
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2025-05-08
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 200
- Registration Number
- NCT06963021
- Locations
- 🇺🇸
Neurocrine Clinical Site, New York, New York, United States
🇺🇸Neurocrine Clincial Site, New York, New York, United States
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 200
- Registration Number
- NCT06911112
- Locations
- 🇺🇸
Neurocrine Clinical Site, Saint Charles, Missouri, United States
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 200
- Registration Number
- NCT06786624
- Locations
- 🇺🇸
Neurocrine Clinical Site, Everett, Washington, United States
Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 7
- Registration Number
- NCT06312189
- Locations
- 🇨🇦
Neurocrine Clinical Site, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 72
- Registration Number
- NCT06267846
- Locations
- 🇺🇸
Neurocrine Clinical Site, Richardson, Texas, United States
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
Phase 4
Completed
- Conditions
- Schizoaffective DisorderMajor Depressive DisorderTardive DyskinesiaSchizophreniaBipolar Disorder
- Interventions
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 59
- Registration Number
- NCT05859698
- Locations
- 🇺🇸
Neurocrine Clinical Site, Houston, Texas, United States
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 8
- Registration Number
- NCT05654870
- Locations
- 🇺🇸
Neurocrine Clinical Site, Atlanta, Georgia, United States
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 213
- Registration Number
- NCT05545111
- Locations
- 🇺🇸
Neurocrine Clinical Site, Richardson, Texas, United States
🇺🇸Neurocrine Clinical site, Saint Louis, Missouri, United States